• Arbutus Biopharma swung to third-quarter 2026 net income of $59.12 million from a year-earlier loss.
• Revenue fell 43% year over year to $299,000, primarily due to lower license royalty revenue.
• Cash, cash equivalents and marketable securities totaled $337.49 million at September 30; an October tender offer returned $230 million to shareholders.
• Arbutus and Genevant expanded patent enforcement against Pfizer/BioNTech with new Japanese lawsuits and an additional patent claim in Canada.
• The FDA lifted the clinical hold on AB-101 in October, allowing additional US clinical development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arbutus Biopharma Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611100730PRIMZONEFULLFEED9874267) on November 10, 2026, and is solely responsible for the information contained therein.